Since there is a lot of info on supplements on here, I figures I'd share this. And a while back we were talking about pulmozyme being effective for some people and not in others. So let's see if I can figure this out...
Genetics & Environmental Law Weekly
December 16, 2006
FIBROSIS;
Scientists at Ghent University target fibrosis
SECTION: EXPANDED REPORTING; Pg. 95
LENGTH: 446 words
Scientists discuss in "Role of magnesium in the failure of rhDNase therapy in
patients with cystic fibrosis" new findings in fibrosis. According to recent
research from Ghent, Belgium, "In the management of cystic fibrosis (CF),
rhDNase-I inhalation is widely used to facilitate the removal of the highly
viscous and elastic mucus (often called sputum) from the lungs. However, an
important group of CF patients does not benefit from rhDNase-I treatment."
"A study was undertaken to elucidate the reason for the failure of rhDNase-I in
these patients and to evaluate strategies to overcome this. The biochemical
properties, physical properties, and degradation by rhDNase-I of sputum obtained from clinical responders and non-responders to rhDNase-I were compared, and the
ability of magnesium to reactivate rhDNase-I in DNA solutions and in sputum was
investigated. The effect of oral magnesium supplements on magnesium levels in
the sputum of patients with CF was also examined. Sputum from clinical
responders was extensively degraded in vitro on incubation with rhDNase-I, while
sputum from clinical non-responders was not degraded: the median decrease in
sputum elasticity in the two groups was 32% and 5%, respectively. Sputum from
clinical responders contained significantly higher concentrations of magnesium
than sputum from non-responders (2.0 mM v 1.3 mM; p=0.020). Sputum that could
not be degraded by rhDNase-I became degradable after preincubation with
magnesium. The effect of magnesium on rhDNase-I activity was mediated through
actin," wrote N.N. Sanders and colleagues, Ghent University.
The researchers concluded: "Oral intake of magnesium enhanced the magnesium
concentration in the sputum of CF patients. Increasing the magnesium concentration in sputum by, for example,
oral magnesium supplements may be a promising new strategy to overcome the
failure of rhDNase-I in patients with CF."
Genetics & Environmental Law Weekly
December 16, 2006
FIBROSIS;
Scientists at Ghent University target fibrosis
SECTION: EXPANDED REPORTING; Pg. 95
LENGTH: 446 words
Scientists discuss in "Role of magnesium in the failure of rhDNase therapy in
patients with cystic fibrosis" new findings in fibrosis. According to recent
research from Ghent, Belgium, "In the management of cystic fibrosis (CF),
rhDNase-I inhalation is widely used to facilitate the removal of the highly
viscous and elastic mucus (often called sputum) from the lungs. However, an
important group of CF patients does not benefit from rhDNase-I treatment."
"A study was undertaken to elucidate the reason for the failure of rhDNase-I in
these patients and to evaluate strategies to overcome this. The biochemical
properties, physical properties, and degradation by rhDNase-I of sputum obtained from clinical responders and non-responders to rhDNase-I were compared, and the
ability of magnesium to reactivate rhDNase-I in DNA solutions and in sputum was
investigated. The effect of oral magnesium supplements on magnesium levels in
the sputum of patients with CF was also examined. Sputum from clinical
responders was extensively degraded in vitro on incubation with rhDNase-I, while
sputum from clinical non-responders was not degraded: the median decrease in
sputum elasticity in the two groups was 32% and 5%, respectively. Sputum from
clinical responders contained significantly higher concentrations of magnesium
than sputum from non-responders (2.0 mM v 1.3 mM; p=0.020). Sputum that could
not be degraded by rhDNase-I became degradable after preincubation with
magnesium. The effect of magnesium on rhDNase-I activity was mediated through
actin," wrote N.N. Sanders and colleagues, Ghent University.
The researchers concluded: "Oral intake of magnesium enhanced the magnesium
concentration in the sputum of CF patients. Increasing the magnesium concentration in sputum by, for example,
oral magnesium supplements may be a promising new strategy to overcome the
failure of rhDNase-I in patients with CF."